{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vertigo/prescribing-information/cinnarizine/","result":{"pageContext":{"chapter":{"id":"edb82728-4773-5ae4-81a1-a8069cbef357","slug":"cinnarizine","fullItemName":"Cinnarizine","depth":2,"htmlHeader":"<!-- begin field 0d9244c0-d576-4723-aafa-a84800c4526f --><h2>Cinnarizine</h2><!-- end field 0d9244c0-d576-4723-aafa-a84800c4526f -->","summary":"","htmlStringContent":"<!-- begin item f8687912-75ba-4f55-a2e5-a84800c45018 --><!-- end item f8687912-75ba-4f55-a2e5-a84800c45018 -->","topic":{"id":"b94ca2c5-94f9-5b0b-8947-d7ed33aa5095","topicId":"d75cb8e1-a405-4add-9416-f4ddd4be71a4","topicName":"Vertigo","slug":"vertigo","lastRevised":"Last revised in November 2020","chapters":[{"id":"7cfbf245-8080-5408-b5af-46e6b015eaac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"eb7fafc8-c3da-5207-80f3-b71728b95977","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1a3b8a24-9e4d-5ef6-8305-9df3b1c317f2","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6c0480e-9ea3-560b-9ef9-010e2b6d6bc3","slug":"changes","fullItemName":"Changes"},{"id":"1d87a170-6a07-5578-be1a-88233309a577","slug":"update","fullItemName":"Update"}]},{"id":"3b505c43-ded3-5313-b4a7-fe0a2d033ba5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"53494a81-9a2a-5d95-bf7d-e77e711c0574","slug":"goals","fullItemName":"Goals"},{"id":"e1f01a8c-4094-553b-a76c-f2dd90a51b2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1cfd513c-3d5a-54aa-9602-3e6d3be38cba","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"25093d8c-33f4-5be7-9754-8089a9704300","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"969ceb1b-e8dd-5bee-8648-365304bee682","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"568bc797-4e2c-59a2-b4f8-b797d90d60b1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3f307c6b-3ea3-5ffd-8491-82b6cc0395f9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"afc89990-521e-5fdd-ae17-ac351fe1d354","slug":"definition","fullItemName":"Definition"},{"id":"17376a5d-724c-5d04-a438-253fe0405224","slug":"causes","fullItemName":"Causes"},{"id":"d4691641-4de6-57f1-a02a-a9d5537caa0d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a5e55fa5-72d9-5ff4-923d-151c33d24a62","slug":"complications","fullItemName":"Complications"},{"id":"8264cee3-d774-5e04-a336-cbfe45355b60","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"375a4e7f-7fd0-5036-a3cc-6a0679c13bfa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ac52451f-5469-5c2c-8dee-9d89ff20b1fb","slug":"confirming-vertigo","fullItemName":"Confirming vertigo"},{"id":"c5647bfa-8ae2-597f-b367-8710ae469632","slug":"assessment","fullItemName":"Assessment"},{"id":"32b446b7-58ea-516a-9ba6-89e9bd5dfd13","slug":"determining-the-cause","fullItemName":"Determining the cause"}]},{"id":"47662437-22e1-5dc4-889b-55ff8cffa7c9","fullItemName":"Management","slug":"management","subChapters":[{"id":"c7179f67-2fd1-5f8f-8486-60029021ba78","slug":"central-vertigo","fullItemName":"Scenario: Central vertigo"},{"id":"fd3025fe-2a3b-5653-ae93-d9e6f65503c3","slug":"peripheral-vertigo","fullItemName":"Scenario: Peripheral vertigo"}]},{"id":"2947932c-9f33-58ca-8926-c2a8a66f953c","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"edb82728-4773-5ae4-81a1-a8069cbef357","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"0d4b2274-af67-500e-a840-fcd41623b09e","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"981f2355-58ab-5b91-b56a-649ae876203f","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"edf7a80f-dfc3-5b9c-a678-82dd7acddfbb","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"2b7a5cd7-2c2c-5be4-89b5-e3146e3c36e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3832ba17-fb19-511b-b3de-fc89bc2a3346","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bdd9780-7f08-58bd-bd56-e5043164ffdc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b8bb4197-e5b5-5db7-876b-584f0ac43071","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d2c7a7b5-0d16-58aa-926f-96fa0fae0f86","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f217b9f5-f617-534d-bfb1-86ca071d3288","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"614e67fc-1003-5f73-90ed-fcc6fa8adc67","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a11a0d07-8592-5c4c-89c6-b318893454cd","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2947932c-9f33-58ca-8926-c2a8a66f953c","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"483027bd-eeca-5b2d-9884-485089872217","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 9569cf70-ffec-4c8e-ae08-a84801026c72 --><h3>What dosage of cinnarizine should I prescribe?</h3><!-- end field 9569cf70-ffec-4c8e-ae08-a84801026c72 -->","summary":"","htmlStringContent":"<!-- begin item 63d31744-f323-42e4-b5cd-a84801026999 --><!-- begin field c520dfad-bcf0-4aa4-a0df-a84801026c72 --><p>For vestibular symptoms, prescribe oral cinnarizine 30 mg three times a day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>].</p><p> </p><!-- end field c520dfad-bcf0-4aa4-a0df-a84801026c72 --><!-- end item 63d31744-f323-42e4-b5cd-a84801026999 -->","subChapters":[]},{"id":"6f362ed0-53d4-53f3-b021-66e652a156f4","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3efd9887-c0de-4f37-942e-a8480102865d --><h3>What are the contraindications and cautions when prescribing cinnarizine?</h3><!-- end field 3efd9887-c0de-4f37-942e-a8480102865d -->","summary":"","htmlStringContent":"<!-- begin item c81f3339-e5b3-43fc-9727-a848010284e0 --><!-- begin field 44dc73f0-8293-4a11-9f49-a8480102865d --><ul><li>Do not prescribe cinnarizine if the person:<ul><li>Is hypersensitive to cinnarizine or any of its excipients.</li><li>Has porphyria.</li><li>Has severe liver disease (there is an increased risk of coma).</li></ul></li><li>Prescribe cinnarizine with caution if the person has:<ul><li>Parkinson’s disease – give only if the advantages outweigh the risk of disease exacerbation.</li><li>Hepatic or renal impairment.</li><li>Epilepsy.</li><li>Prostatic hypertrophy.</li><li>Pyloroduodenal obstruction.</li><li>Susceptibility to angle closure glaucoma.</li><li>Urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>]</p><p> </p><!-- end field 44dc73f0-8293-4a11-9f49-a8480102865d --><!-- end item c81f3339-e5b3-43fc-9727-a848010284e0 -->","subChapters":[]},{"id":"26be5357-e8a6-5b54-a595-22e4779e4a64","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ad49bda5-3d54-4bea-90c2-a84801029c98 --><h3>What are the adverse effects of cinnarizine?</h3><!-- end field ad49bda5-3d54-4bea-90c2-a84801029c98 -->","summary":"","htmlStringContent":"<!-- begin item e580ceb4-1b27-45a1-b014-a84801029940 --><!-- begin field 0fcabac9-82b9-4bfe-a1d3-a84801029c98 --><ul><li>Adverse effects of cinnarizine are more common in older people and include drowsiness, nausea, dyspepsia, and weight gain.</li><li>Less common adverse effects include:<ul><li>Anaphylaxis, angio-oedema.</li><li>Dyskinesia, extrapyramidal disorder, Parkinsonism, tremor, convulsions.</li><li>Cholestatic jaundice.</li><li>Palpitations.</li><li>Bronchospasm.</li><li>Subacute cutaneous lupus erythematosus, lichen planus, photosensitivity reactions, rashes.</li><li>Angle-closure glaucoma.</li><li>Confusion, depression.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>]</p><p> </p><!-- end field 0fcabac9-82b9-4bfe-a1d3-a84801029c98 --><!-- end item e580ceb4-1b27-45a1-b014-a84801029940 -->","subChapters":[]},{"id":"9e4714e0-ff28-535a-81c0-ee347184e936","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1757c8c0-2075-47b4-be19-a8480102b412 --><h3>What drug interactions occur with cinnarizine?</h3><!-- end field 1757c8c0-2075-47b4-be19-a8480102b412 -->","summary":"","htmlStringContent":"<!-- begin item 0371ca50-b64c-45c5-ade9-a8480102b27b --><!-- begin field d97467bd-ab2a-4b53-ac10-a8480102b412 --><ul><li>Concurrent use of cinnarizine and alcohol, CNS depressants, or tricyclic antidepressants may result in increased sedative effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2017a</a>]. Advise that this may influence the ability to perform skilled tasks such as driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>].  </li><li>The use of phenelzine in conjunction with cinnarizine increases the risk of antimuscarinic adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">BNF 74, 2017</a>].  </li><li>Avoid using cinnarizine within 4 days of skin testing as it may influence the results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vertigo/references/\">ABPI Medicines Compendium, 2017a</a>].  </li></ul><!-- end field d97467bd-ab2a-4b53-ac10-a8480102b412 --><!-- end item 0371ca50-b64c-45c5-ade9-a8480102b27b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}